EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

NCT01008475 | Completed Phase 1 Results

• 1 other identifier: EMR62242-004
• Study Type: interventional
• Target: 232
• Locations: 12 countries
• Sites: 62

Brief Summary

The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras wildtype metastatic colorectal cancer patients.

Conditions

Metastatic Colorectal Cancer

Keywords

EMD 525797; Cetuximab; Irinotecan; metastatic colorectal cancer

Outcome Measures

Primary Outcomes (2)

• Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity)

  DLT was defined as any Grade 4 hematologic toxicity or Grade 3/4 non-hematologic toxicity assessed as related to trial treatment by the Investigator and/or Sponsor and confirmed by the safety monitoring committee (SMC) to be relevant to the combination treatment within the first cycle of therapy. Any Grade 3 or 4 non haematological toxicity, any Grade 4 hematological toxicity, treatment related deaths within the first 2 weeks of therapy. Toxicities excluded from DLT: alopecia, rash, nausea, vomiting and hypomagnesemia of Grade 3 or 4 severity, Grade 4 neutropenia or leukopenia lasting for =\< 5 days and not associated with fever; Single laboratory values out of normal range without any clinical correlation and resolve within 7 days; Grade 3 or 4 diarrhoea without adequate supportive care. Adequate supportive care has been administered and Grade 4 diarrhea persists (investigator decision); isolated Grade 4 lymphocytopenia and thrombocytopenia without clinical correlation.

  Time from the first dose of study drug up to 2 weeks

• Randomized Part: Progression Free Survival (PFS)

  PFS was defined as the time from the randomization date to first documented sign of objective radio-graphic disease progression (PD) as per Response Evaluation Criteria In Solid Tumors version 1. (RECIST 1.0) or death from any cause if reported within 12 weeks from the last tumor assessment. PD per RECIST v 1.0 was defined as at least 20% increase in the sum of the longest diameter of target lesions, taking as the reference the smallest sum of longest diameters recorded since treatment started, or unequivocal progression of existing non-target lesion or appearance of new lesions. Subjects who did not progress or died at the time of analyses, or subjects who died without previously radio-graphically documented PD and death was observed after more than 12 weeks of last tumor assessment without progression, these subjects were censored at their last tumor assessment date or date of randomization, whichever occurred last.

  Time from randomization until progressive disease or death; assessed up to 18 months (i.e data cut-off date: 09 Oct 2013)

Secondary Outcomes (4)

• Overall Survival (OS) Time

  Time from randomization until death assessed up to 18 months (i.e data cut-off date: 09 Oct 2013)

• Time to Progression (TTP)

  Time from randomization until disease progression assessed up to 18 months (i.e data cut-off date: 09 Oct 2013)

• Number of Subjects With Tumor Response

  Time from randomization up to 18 months (i.e data cut-off date: 09 Oct 2013)

• Time to Treatment Failure (TTF)

  Time from randomization until discontinuation assessed up to 18 months (i.e data cut-off date: 09 Oct 2013)

Study Arms (7)

Safety part: EMD 525797 250 mg + Standard of Care (SoC)

EXPERIMENTAL

EMD 525797 250 mg in combination with cetuximab and irinotecan

Drug: EMD 525797 250 mg; Drug: Cetuximab; Drug: Irinotecan

Safety part: EMD 525797 500 mg + SoC

EXPERIMENTAL

EMD 525797 500 mg in combination with cetuximab and irinotecan

Drug: EMD 525797 500 mg; Drug: Cetuximab; Drug: Irinotecan

Safety part: EMD 525797 750 mg + SoC

EXPERIMENTAL

EMD 525797 750 mg in combination with cetuximab and irinotecan

Drug: EMD 525797 750 mg; Drug: Cetuximab; Drug: Irinotecan

Safety part: EMD 525797 1000 mg + SoC

EXPERIMENTAL

EMD 525797 1000 mg in combination with cetuximab and irinotecan

Drug: EMD 525797 1000 mg; Drug: Cetuximab; Drug: Irinotecan

Randomized part: EMD 525797 500 mg + SoC

EXPERIMENTAL

EMD 525797 500 mg in combination with cetuximab and irinotecan

Drug: EMD 525797 500 mg; Drug: Cetuximab; Drug: Irinotecan

Randomized Part: EMD 525797 1000 mg + SoC

EXPERIMENTAL

EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)\] in combination with cetuximab and irinotecan.

Drug: EMD 525797 1000 mg; Drug: Cetuximab; Drug: Irinotecan

Randomized Part: SoC

OTHER

Cetuximab and irinotecan

Drug: Cetuximab; Drug: Irinotecan

Interventions

EMD 525797 250 mg DRUG

EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .

Safety part: EMD 525797 250 mg + Standard of Care (SoC)

EMD 525797 500 mg DRUG

Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent . Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.

Randomized part: EMD 525797 500 mg + SoC; Safety part: EMD 525797 500 mg + SoC

EMD 525797 750 mg DRUG

EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .

Also known as: Abituzumab

Safety part: EMD 525797 750 mg + SoC

EMD 525797 1000 mg DRUG

Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent . Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.

Also known as: Abituzumab

Randomized Part: EMD 525797 1000 mg + SoC; Safety part: EMD 525797 1000 mg + SoC

Cetuximab DRUG

Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT. Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.

Randomized Part: EMD 525797 1000 mg + SoC; Randomized Part: SoC; Randomized part: EMD 525797 500 mg + SoC; Safety part: EMD 525797 1000 mg + SoC; Safety part: EMD 525797 250 mg + Standard of Care (SoC); Safety part: EMD 525797 500 mg + SoC; Safety part: EMD 525797 750 mg + SoC

Irinotecan DRUG

Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent . Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.

Randomized Part: EMD 525797 1000 mg + SoC; Randomized Part: SoC; Randomized part: EMD 525797 500 mg + SoC; Safety part: EMD 525797 1000 mg + SoC; Safety part: EMD 525797 250 mg + Standard of Care (SoC); Safety part: EMD 525797 500 mg + SoC; Safety part: EMD 525797 750 mg + SoC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with histologically confirmed kras wildtype (WT) colorectal carcinoma (CRC) with documented distant metastasis
• Prior oxaliplatin/fluoropyrimidine-containing regimen for the first-line treatment of metastatic disease
• Failed an oxaliplatin regimen for metastatic colorectal carcinoma (mCRC). Failure is defined as either progressive disease (PD) (clinical or radiologic) within 6 months of the last dose of any agent of an oxaliplatin-based regimen or intolerance to an oxaliplatin regimen. Intolerance to an oxaliplatin regimen is defined as discontinuation due to any of the following: severe allergic reaction, persistent severe neurotoxicity, or delayed recovery from toxicity preventing retreatment
• At least 1 radiographically documented measurable lesion in a previously non irradiated area according to Response Evaluation Criteria In Solid Tumors (RECIST, Version 1.0), i.e., this lesion must be adequately measurable in at least 1 dimension (longest diameter to be recorded) as greater than or equal to (\>=) 2 centimeter (cm) by conventional techniques or \>=1 cm by spiral computed tomography (CT) scan
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, or Karnofsky performance status (KPS) \>= 80 percent (%)
• Absolute Neutrophil Count (ANC) \>=1.5 x 10\^9/Liter
• Platelets \>=100 x 10\^9/Liter
• Hemoglobin \>=9 gram per deciliter (g/dL) (without transfusions)
• Bilirubin less than or equal to (\<=) 1.5 x upper limit normal (ULN)
• Aspartate transaminase (AST) \<=5 x ULN and alanine transaminase (ALT) \<=5 x ULN
• Serum creatinine \<=1.25 x ULN and/or creatinine clearance \>=50 milliliter per minute (mL/min)
• International Nationalized Ratio (INR), and partial thromboplastin time (PTT) within normal limits
• Sodium and potassium within normal limits or \<=10% above or below (supplementation permitted)

You may not qualify if:

• Previous treatment with any inhibitor of Epidermal Growth Factor Receptor (EGFR)
• Known brain metastasis and/or leptomeningeal disease
• Radiotherapy (except localized radiotherapy for pain relief), major surgery, or any investigational drug in the 30 days before the start of trial treatment entry; planned major surgery during the trial
• Concurrent chronic systemic immune or hormone therapy not indicated in this trial protocol (except for physiologic replacement; steroids up to 10 mg of prednisone equivalent or topical and inhaled steroids are allowed)
• Clinically relevant coronary artery disease (New York Heart Association \[NYHA\] functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
• Uncontrolled hypertension defined as systolic blood pressure \>=160 millimeter of mercury (mmHg) and/or diastolic blood pressure \>=100 mmHg under resting conditions
• History of coagulation disorder associated with bleeding or recurrent thrombotic events
• History of recent peptic ulcer disease (endoscopically proven gastric, duodenal or esophageal ulcer) within 6 months of trial treatment start
• Chronic inflammatory bowel disease, or acute/chronic ileus
• Active infection (requiring i.v. antibiotics), including active tuberculosis, active or chronic Hepatitis B or C, or ongoing HIV infection

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead

Study Sites (62)

Research Site

Brussels, Belgium

Location

Research Site

Edegem, Belgium

Location

Research Site

Ghent, Belgium

Location

Research Site

Leuven, Belgium

Location

Research Site

Sofia, Bulgaria

Location

Research Site

Stróvolos, Nicosia, Cyprus

Location

Research Site

Brno, Czechia

Location

Research Site

Hořovice, Czechia

Location

Research Site

Kutná Hora, Czechia

Location

Research Site

Olomouc, Czechia

Location

Research Site

Pardubice, Czechia

Location

Research Site

Prague, Czechia

Location

Research Site

Dresden, Germany

Location

Research Site

Essen, Germany

Location

Research Site

Freiburg im Breisgau, Germany

Location

Research Site

Hamburg, Germany

Location

Research site

Hanover, Germany

Location

Research Site

Heilbronn, Germany

Location

Research Site

Landshut, Germany

Location

Research Site

Leipzig, Germany

Location

Research Site

Munich, Germany

Location

Research Site

Recklinghausen, Germany

Location

Research Site

Ulm, Germany

Location

Research Site

Thessaloniki, Cyprus, Greece

Location

Research Site

Mournies Chania, Greece

Location

Research Site

Budapest, Hungary

Location

Research Site

Győr, Hungary

Location

Research Site

Kecskemét, Hungary

Location

Research Site

Miskolc, Hungary

Location

Research Site

Nyíregyháza, Hungary

Location

Research Site

Szolnok, Hungary

Location

Research Site

Haifa, Israel

Location

Research Site

Jerusalem, Israel

Location

Research Site

Ramat Gan, Israel

Location

Research Site

Rehovot, Israel

Location

Research Site

Tel Aviv, Israel

Location

Research Site

Elblag, Poland

Location

Research Site

Gdansk, Poland

Location

Research Site

Gliwice, Poland

Location

Research Site

Lodz, Poland

Location

Research Site

Rybnik, Poland

Location

Research Site

Warsaw, Poland

Location

Research

Arkhangelsk, Russia

Location

Research Site

Moscow, Russia

Location

Research Site

Novosibirsk, Russia

Location

Research Site

Omsk, Russia

Location

Research Site

Saint Petersburg, Russia

Location

Research Site

Tomsk, Russia

Location

Research Site

Barcelona, Spain

Location

Research Site

Elche, Spain

Location

Research Site

Madrid, Spain

Location

Research Site

Mallorca, Spain

Location

Research Site

Santander, Spain

Location

Research Site

Santiago de Compostela, Spain

Location

Research Site

Terrassa, Spain

Location

Research Site

Valencia, Spain

Location

Research Site

Aberdeen, United Kingdom

Location

Research Site

Glasgow, United Kingdom

Location

Research Site

London, United Kingdom

Location

Research Site

Manchester, United Kingdom

Location

Research Site

Nottingham, United Kingdom

Location

Research Site

Sutton, United Kingdom

Location

Related Publications (1)

• Elez E, Kocakova I, Hohler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csoszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-140. doi: 10.1093/annonc/mdu474. Epub 2014 Oct 15.

  PMID: 25319061 DERIVED

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Abituzumab; Cetuximab; Irinotecan

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Camptothecin; Alkaloids; Heterocyclic Compounds

Results Point of Contact

• Title: Merck KGaA Communication Center
• Organization: Merck KGaA

service@merckgroup.com

+49-6151-72-5200

Study Officials

• Medical Responsible

  Merck KGaA, Darmstadt, Germany

  STUDY DIRECTOR

• Prof. Josep Tabernero

  HU Vall d' Hebron, Servei d'oncologia. E difici General

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2009
• First Posted: November 5, 2009
• Study Start: October 1, 2009
• Primary Completion: April 1, 2015
• Study Completion: April 1, 2015
• Last Updated: March 30, 2016
• Results First Posted: March 30, 2016

Record last verified: 2016-02

Locations

PL (6); ES (8); GB (6); IL (5); CY (1); BU (1); DE (11); BE (4); GR (2); RU (6); CZ (6); HU (6)